The Business of Biofabrication

A Berlin and Boston-based tissue engineering company has raised €10 million to move living, vascularized human tissue implants through preclinical validation and closer to patients. Cellbricks Therapeutics announced the financing on March 25, 2026, framing it as the capital needed to do the hard translational work the field has long demanded but rarely seen executed.

The Funding Structure

The raise combines a €7 million seed round led by Silicon Roundabout Ventures, with participation from existing backers ACT Venture Partners and a group of long-term investors, alongside more than €3 million in non-dilutive funding from SPRIND, Germany’s Federal Agency for Breakthrough Innovation. The non-dilutive component is described as currently under negotiation.

SPRIND invests approximately €250 million annually in European breakthrough technologies. Its participation alongside private venture capital follows a pattern increasingly common in European deep tech, where federal innovation agencies provide early validation that reduces risk for commercial co-investors. That a government-backed breakthrough innovation agency is funding a tissue biofabrication company signals institutional confidence in the field’s translational readiness, not just its scientific promise.

What the Company Is Building

Cellbricks has developed a proprietary biofabrication platform capable of producing vascularized human tissue implants, meaning engineered tissue constructs that contain functional vessel architecture and are designed to integrate with the patient’s circulatory system after implantation.

Vascularization is the central unsolved engineering challenge in tissue fabrication at clinical scale. Without an internal capillary network, tissue constructs beyond a few hundred microns in thickness cannot sustain viable cells. Every serious effort to produce implantable tissue of meaningful size runs into this problem, and how a company solves it, or fails to, determines whether its constructs can work in a patient rather than only in a dish.

Cellbricks’ platform is built around solving this at the manufacturing level. The company’s constructs are designed not merely to fill a structural void but to survive, vascularize, and function in a living body.

The Lead Program: Soft Tissue Repair, Wound Care, and Trauma

The company’s immediate clinical focus is on major unmet needs in reconstructive surgery, wound healing, and trauma care. The patient populations described in the press release include people with severe soft tissue loss, complex wounds such as full-thickness burns and blast injuries, and reconstructive defects where current options remain inadequate.

For these patients, medicine currently offers a difficult set of compromises: invasive autologous grafting procedures that create donor site morbidity, synthetic implants that restore shape without restoring biology, and solutions that consistently fall short of living functional tissue. Cellbricks frames its lead adipose tissue implant program as a biological alternative to these approaches, aiming for better repair, better integration, and better functional outcomes. Breast reconstruction is cited as one application within this broader soft tissue defect category, not the primary framing of the program.

The €10 million in new capital will fund three preclinical animal studies and generate the translational evidence required to advance toward human clinical studies.

Excitement and Challenges

What makes Cellbricks’ position genuinely compelling is the specificity of the clinical problem it is attacking. Severe soft tissue loss from burns, blast injuries, and reconstructive defects represents a category of patients where medicine has made limited progress for decades. If a living, vascularized adipose construct can be shown to integrate and function in these contexts, it would mark a qualitative shift in what reconstructive surgery can offer, not an incremental improvement on existing materials but a biologically different class of solution. The combination of SPRIND’s backing and private venture capital also suggests the company is being taken seriously by institutions with demanding technical and translational standards, which matters at this stage.

The challenges are equally real. Vascularization in vivo remains the field’s hardest problem: demonstrating that vessel networks formed during fabrication can successfully connect to the host circulation after implantation, and sustain the construct long enough to generate meaningful clinical benefit, has not yet been achieved at scale by any company. Manufacturing consistency is a second constraint, producing tissue constructs that are sufficiently uniform to support a regulatory submission requires process controls that most biofabrication platforms are still building. Regulatory pathways for living tissue implants are less established than for biologics or devices, meaning Cellbricks will be navigating novel territory with regulators in parallel with its preclinical work. And €10 million, while meaningful for early validation, is a modest sum relative to the capital typically required to carry a novel therapeutic through to clinical proof-of-concept. Follow-on financing will need to come, and the preclinical data generated in this round will determine how favourable the terms are.

None of these challenges are disqualifying, but they are the ones the company will need to answer clearly over the next two to three years.

The Longer Horizon

This sequencing is defensible and increasingly common among the more serious players in the biofabrication space. Generating robust preclinical data on a well-defined soft tissue program builds the scientific and regulatory foundation that organ-scale programs will eventually require. The companies most likely to reach organ bioprinting are those that first demonstrate they can make simpler tissue constructs work reliably in translational models. The capital is now in place. The preclinical work is next.

Original article here.